Table 2.
Association between clinical features and adipsin levels for each group of patients. Linear regression models for bivariate and multivariate analysis.
| Healthy controls (n=88) | Early-RA (n=66) | Established-RA (n=98) | axSpa (n=69) | |||||
|---|---|---|---|---|---|---|---|---|
| Variable | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate |
| Age (years) | -0.002 (-0.007-0.004) |
_ | 0.01 (-0.003-0.02) |
– |
0.02
(0.01-0.03)* |
0.01
(0.007-0.028)* |
0.004 (-0.001-0.10) |
– |
| Sex (ref male) |
0.16
(0.02-0.30)* |
– |
0.48
(0.04-0.91)* |
0.46
(0-42-0.88)* |
0.16 (-0.20-0.56) |
– | 0.05 (-0.08-0.19) |
– |
| BMI (kg/m2) | – | – | 0.008(-0.04-0.05) | – | 0.02 (-0.00-0.05) |
– | 0.007 (-0.007-0.021) |
– |
| Disease duration (years) | – | – | – | – |
0.02
(0.01-0.04)* |
0.02
(0.005-0.036)* |
0.011
(0-005-0.18)* |
– |
| RF | – | – | 0.06 (-0.48-0.34) |
– | -0.21 (-0.56-0.12) |
– | – | – |
| ACPA | – | – | -0.25 (-0.67-0.16) |
– | 0.13 (-0.23-0.50) |
– | – | – |
| HLA-B27 | – | – | – | – | – | – | 0.04 (-0.10-0.19) |
– |
| CRP | – | – | -0.006 (-0.21-0.008) |
– | 0.00 (-0.009-0.009) |
– |
0.003*
(0.000-0.005) |
– |
| DAS28 | – | – | 0.02 (-0.13-0.18) |
– | -0.07 (-0.19-0.03) |
– | – | – |
| ASDAS | – | – | – | – | – | – | 0.06 (-0.007-0.04) |
– |
| csDMARDs | – | – | – | – | -0.32 (-0.88-0.23) |
– | 0.09 (-0.04-0.23) |
– |
| Prednisone (ref yes) | – | – |
0.55
(0.12-0.99)* |
0.52
(0.10-0.95)* |
-0.02 (-0.31-0.26) |
– | – | – |
Data of univariate and multivariate analysis of linear regression are expressed by B coefficient and 95% Confidence intervals. Results marked in bold and * are statistically significant. ACPA, anti–citrullinated peptide antibody; ASDAS, Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, 28-joint Disease Activity Score; HLA-B27, human leukocyte antigen B27; RA, rheumatoid arthritis; RF, rheumatoid factor; axSpA, axial spondyloarthritis.